Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma - An interobserver correlative and immunohistochemical study of 32 cases

被引:52
作者
Han, Guangming [1 ,2 ,3 ]
Gilks, C. Blake [1 ,2 ,3 ]
Leung, Samuel [1 ,2 ,3 ]
Eivanowich, Carol A. [4 ,5 ]
Irving, Julie A. [1 ,2 ,3 ]
Longacre, Teri A. [6 ]
Soslow, Robert A. [7 ]
机构
[1] Vancouver Gen Hosp, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Lab Med, Vancouver, BC V5Z 1M9, Canada
[4] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada
[5] Royal Alexandra Hosp, Edmonton, AB, Canada
[6] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
ovarian carcinoma; clear cell; serous; mixed epithelial carcinoma; diagnostic reproducibility;
D O I
10.1097/PAS.0b013e318164edf7
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
There are conflicting data about chemoresistance and prognosis in ovarian clear cell carcinoma (CCC). This could be due to significant interobserver variation in the diagnosis of CCC and other ovarian surface epithelial tumors containing clear cells. Thirty-two cases previously diagnosed as CCC, highgrade ovarian serous carcinoma (SC), and mixed surface epithelial carcinoma (SEC) with clear cell and serous components were reviewed by 4 gynecologic pathologists blinded to the original diagnoses. Interobserver reproducibility was evaluated. Each case was also assessed using immunohistochemical markers Wilm tumor 1, estrogen receptor, and p53. The interobserver reproducibility was greatest for pure CCC (kappa of 0.82), and lowest for the mixed SEC (kappa of 0.32). Moderate agreement was seen in the pure SC category (K of 0.59). All pure SC and most mixed SEC presented as stage III or IV diseases. Most pure CCC presented as stage I or II diseases. Immunoreactivities of the mixed SECs were similar to those of pure SC, but significantly different from those of pure CCC for Wilm tumor 1 (P = 0.0011 for both components), estrogen receptor (P = 0.0003 for clear cell component, P = 0.0061 for serous component), and p53 (P = 0.0062 for both components). The serous and clear cell components of mixed SEC showed higher mitotic rates than pure CCC (P = 0.004 and P = 0.023, respectively), but the mitotic rate of pure SC was similar to the mixed SEC. We conclude that (1) pure CCC is reproducibly diagnosed. (2) The diagnosis of mixed ovarian SEC with clear cell component is not reproducible. (3) Mixed SEC with clear cell and serous components show similar stage, mitotic activities, and immunoreactivities to those of pure SC, and likely represent SC with clear cell changes.
引用
收藏
页码:955 / 964
页数:10
相关论文
共 49 条
  • [11] Geisler JP, 2002, JNCI-J NATL CANCER I, V94, P61
  • [12] Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease
    Goff, BA
    delaCuesta, RS
    Muntz, HG
    Fleischhacker, D
    Ek, M
    Rice, LW
    Nikrui, N
    Tamimi, HK
    Cain, JM
    Greer, BE
    Fuller, AF
    [J]. GYNECOLOGIC ONCOLOGY, 1996, 60 (03) : 412 - 417
  • [13] Goldstein NS, 2002, AM J CLIN PATHOL, V117, P541
  • [14] Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study
    Havrilesky, L
    Darcy, KM
    Hamdan, H
    Priore, RL
    Leon, J
    Bell, J
    Berchuck, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (20) : 3814 - 3825
  • [15] UTERINE PAPILLARY SEROUS CARCINOMA - A HIGHLY MALIGNANT FORM OF ENDOMETRIAL ADENOCARCINOMA
    HENDRICKSON, M
    ROSS, J
    EIFEL, P
    MARTINEZ, A
    KEMPSON, R
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (02) : 93 - 108
  • [16] Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396
  • [17] Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease
    Ho, CM
    Huang, YJ
    Chen, TC
    Huang, SH
    Liu, FS
    ChangChien, CC
    Yu, MH
    Mao, TL
    Wang, TY
    Hsieh, CY
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 94 (01) : 197 - 203
  • [18] CLEAR CELL ADENOCARCINOMA OF THE OVARY - A CLINICAL ANALYSIS AND COMPARISON WITH SEROUS CARCINOMA
    JENISON, EL
    MONTAG, AG
    GRIFFITHS, CT
    WELCH, WR
    LAVIN, PT
    GREER, J
    KNAPP, RC
    [J]. GYNECOLOGIC ONCOLOGY, 1989, 32 (01) : 65 - 71
  • [19] WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma
    Kaneuchi, M
    Sasaki, M
    Tanaka, Y
    Shiina, H
    Yamada, H
    Yamamoto, R
    Sakuragi, N
    Enokida, H
    Verma, M
    Dahiya, R
    [J]. CANCER, 2005, 104 (09) : 1924 - 1930
  • [20] OVARIAN CLEAR CELL ADENOCARCINOMA
    KENNEDY, AW
    BISCOTTI, CV
    HART, WR
    WEBSTER, KD
    [J]. GYNECOLOGIC ONCOLOGY, 1989, 32 (03) : 342 - 349